Transdermal estradiol Matches LHRH Agonists in Survival With Different Side Effect Profile in prostate cancer: NEJM
A recent study published in The New England Journal of Medicine found that transdermal estradiol (tE2) therapy was noninferior to luteinizing hormone–releasing hormone (LHRH) agonists in terms of 3-year metastasis-free…